<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036764</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02464</org_study_id>
    <secondary_id>NYU-0057</secondary_id>
    <secondary_id>N01CM17103</secondary_id>
    <secondary_id>CDR0000069320</secondary_id>
    <nct_id>NCT00036764</nct_id>
  </id_info>
  <brief_title>BMS-247550 in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage&#xD;
      IV melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of BMS-247550 in patients with stage IV melanoma. II. Determine the&#xD;
      toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to the number of&#xD;
      prior chemotherapy regimens (0 vs 1-2, including dacarbazine or temozolomide).&#xD;
&#xD;
      Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The 95% confidence intervals will be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time to progression</measure>
    <time_frame>Time from the first day of treatment with BMS 247550 until the first documentation of disease progression, assessed up to 2 years</time_frame>
    <description>Median time to progression will be described for each subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related toxicities graded according to the revised NCI CTC version 2.0</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Related toxicities will be described.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>BMS-247550</other_name>
    <other_name>epothilone B lactam</other_name>
    <other_name>Ixempra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Pharmacogenomic Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IV melanoma&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  Greater than 20 mm by conventional techniques&#xD;
&#xD;
               -  Greater than 10 mm by spiral CT scan&#xD;
&#xD;
          -  Known brain metastases allowed if all of the following criteria are met:&#xD;
&#xD;
               -  Radiologically stable for at least 6 weeks after completion of whole brain&#xD;
                  radiotherapy&#xD;
&#xD;
               -  Stable at time of study&#xD;
&#xD;
               -  No mass effect present radiologically&#xD;
&#xD;
               -  No concurrent steroids to control symptoms of brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior severe allergic reactions (grade III or IV or grade II not responsive to&#xD;
             steroids) to taxanes or medications containing Cremophor EL&#xD;
&#xD;
          -  No pre-existing grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No HIV-positive patients receiving combination antiretroviral therapy&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness that would preclude study&#xD;
&#xD;
          -  Prior vaccine therapy allowed&#xD;
&#xD;
          -  Prior immunotherapy (e.g., interleukin-2 or interferon) allowed&#xD;
&#xD;
          -  Stratum I:&#xD;
&#xD;
               -  No prior chemotherapy&#xD;
&#xD;
          -  Stratum II:&#xD;
&#xD;
               -  No more than 2 prior chemotherapy regimens (must have included dacarbazine or&#xD;
                  temozolomide)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior limb-perfusion therapy allowed (stratum II)&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies intended to&#xD;
             treat malignancy&#xD;
&#xD;
          -  No concurrent Hypericum perforatum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Pavlick</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Clinical Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

